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1. Introduction 
Prothrombin Earcelona is a variant of human 
prothrombin described in four siblings of a Spanish 
family [l] . In homozygous patients’ plasma, this 
variant is characterized by a very low functional 
activity but normal prothrombin level by immuno- 
chemical and staphylocoagulase assays. 
Prothrombin Barcelona which is able to bind 
calcium and to be adsorbed onto barium citrate has 
been purified. It was demonstrated to have the same 
molecular weight but a slightly more anodic electro- 
phoretic mobility than normal prothrombin [2]. The 
purified variant is converted by prothrombinase com- 
plex at a much lower rate than normal prothrombin. 
The assumption was made that this slow activation 
rate could be due to the impairment of one of the 
proteolytic cleavages known to occur in the normal 
activation process. 
Experiments using various activation systems were 
performed in order to test this hypothesis, and their 
results suggest a specific defect in the cleavage by 
factor Xa between fragment 2 (F,) and prethrombin 2 
(P2>. 
2. Materials and methods 
Normal prothrombin was purified from human 
plasma using barium citrate adsorption/elution and 
ammonium sulfate precipitation as in [3] and DEAE 
Sephadex A50 chromatography as in [4] . Prothrombin 
Barcelona was purified as in [2] . Factor Xa was 
prepared from bovine factor X [3] and human 
thrombin from purified prothrombin [ 5 ] . Crude 
human brain cephalin preparation was used as phos- 
pholipid source. Hirudin (Lab. STAGO) was used at 
the final concentration of 200 AT U/mg prothrombin. 
Generation of thrombin clotting activity was 
measured by a two stage assay as in [6]. Treatments 
of prothrombin by thrombin and by Xa were separately 
performed as in [7] . The appearance of the products 
of proteolysis was monitored by acrylamide-SDS gel 
electrophoresis as in [8] . 
The esterase activity was tested spectrophotometri- 
tally on TAMe (p-toluenesulfonyl L arginine methyl 
ester) as in [9]. 
3. Results and discussion 
In the present study, prothrombin activation was 
tested using various partial activation systems (legend 
fig.1). In the presence of Xa, Ca2+ and phospholipids, 
no thrombin clotting activity was generated within 
4 h, a minute amount of such an activity being found 
later. 
The cleavage of prothrombin by thrombin (fig.2) 
gave rise to the appearance of prethrombin 1 (Pi) and 
fragment 1 (Fi ). It was found to be roughly the same 
for both normal and abnormal proteins with a slight 
delay in the latter case. The disappearance of pro- 
thrombin was complete within 1 h in the case of pro- 
thrombin Barcelona. Thus the sensitivity of the 
variant molecule to the action of thrombin can be 
considered to be fairly normal. 
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Fig.1. Activation of prothrombin by factor Xa (5 U/mg pro- 
thrombin): generation of thrombin-clotting activity. Normal 
prothrombin is represented in continuous line and prothrom- 
bin Barcelona in dashed line. Activation system: (n-o) Xa 
alone; (4---a) Xa + 2 mM calcium; (o-o) Xa, calcium + 
phospholipids 40 ng/mg prothrombin. 
Conversely the proteolytic cleavage by factor Xa 
(tig.3) was found to be abnormal in prothrombin 
Barcelona. When compared to the control, the main 
difference observed was the absence of P2 after lh, 
and simultaneously a persistence of a prothrombin 
band and an accumulation of Pr . After 2 h prothrom- 
bin disappeared, Pr was still accumulating and a faint 
band could be seen migrating like P, . Its significance 
is not clear; it could be due either to a very late 
cleavage by Xa or to the second thrombin cleavage 
which occurs 13 residues further as shown [7] to be 
specific of human prothrombin. The Fz -Pz cleavage 
seems therefore to be specifically impaired in 
prothrombin Barcelona. Pr is generated from normal 
prothrombin by a thrombin cleavage between F, and 
Pr . Therefore the accumulation of Pr during the acti- 
Fig.2. Cleavage of prothrombin by thrombin (10 NIH 
units/mg prothrombin). Identification of products formed 
by SDS-polyacrylamide gel (10%) electrophoresis. II, pro- 
thrombin; P,, prethrombin 1; F, , fragment 1. 
vation of prothrombin Barcelona is in discrepancy 
with the absence of any thrombin activity detectable 
by clotting assay (fig.1). Then prothrombin activation 
by Xa was performed in the presence of hirudin, a 
specific thrombin inhibitor. No formation of Pr was 
observed and in the case of prothrombin Barcelona, 
the prothrombin band remained unchanged. Finally 
the generation of an esterase activity was checked on 
0 3&a lh 0 aanin Ih 2h 
Fig.3. Activation of prothrombin by factor Xa (5 U/mg 
prothrombin). SDS-polyacrylamide gel (10%) electropho- 
retie identification of the intermediates of activation with 
disulfide bonds reduced. P, , prethrombin 2; TB, thrombin 
chain B. 
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Fig.4. Esterase activity on TAMe during the activation of 
prothrombin by factor Xa. Normal prothrombin is represented 
in continuous line and prothrombin Barcelona in dashed line. 
Prothrombin 0.1 mg/ml; Xa 5 U/mg prothrombin; Ca*’ 
10 mM; phospholipids 40 pg/mg prothrombin. TAMe 10F3 M 
in buffer 0.04 M Tris, 0.01 M CaCI,, pH 8.1. Hirudin 200 AT 
units/mg prothrombin was added after 45 min incubation. 
TAMe as a result of the treatment of prothrombin by 
factor Xa (tig.4). In these conditions, the generated 
activity was identical with both normal and abnormal 
prothrombin and was similarly inhibited by hirudin. 
Two main abnormal features therefore characterize 
the activation of prothrombin Barcelona by factor Xa: 
(i) The absence of the F2P, Xa-catalyzed cleavage. 
(ii) The generation of a thrombin-like activity 
responsible for the FrPr cleavage and for the 
esterase activity, inhibited by hirudin, but with- 
out any activity toward fibrinogen. 
No definite mechanism can be ascertained up to now, 
but a possible hypothesis can be advanced comparing 
our results with the known activation process of pro- 
thrombin by snake venoms. In these cases the genera- 
tion of high molecular weight intermediates with 
thrombin activity has been shown [lo,1 l] . These 
observations indicate that the generation of thrombin 
activity requires cleavage between the two chains of 
thrombin but not the removal of the ‘pro’ part of the 
molecule (F, and F,). Similarly the thrombin-like 
activity observed during the activation of prothrombin 
Barcelona by Xa could be related to a single Xa 
catalyzed cleavage between the two chains of throm- 
bin, without the F2Pz cleavage, giving rise to an 
active high molecular weight intermediate. 
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